Hit-to-Lead Optimization and Discovery of 5-((5-([1,1′-Biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic Acid (MK-3903): A Novel Class of Benzimidazole-Based Activators of AMP-Activated Protein Kinase-Reference-Cited by-同舟云学术

Hit-to-Lead Optimization and Discovery of 5-((5-([1,1′-Biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic Acid (MK-3903): A Novel Class of Benzimidazole-Based Activators of AMP-Activated Protein Kinase

Published:2017-10-25 Issue:21 Volume:60 Page:9040-9052
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Lan Ping^ORCID,Romero F. Anthony^ORCID,Wodka Dariusz,Kassick Andrew J.,Dang Qun¹,Gibson Tony¹,Cashion Daniel¹,Zhou Gaochao,Chen Yuli,Zhang Xiaoping,Zhang Aihua,Li Ying,Trujillo Maria E.,Shao Qing,Wu Margaret,Xu Shiyao,He Huaibing,MacKenna Deidre¹,Staunton Jocelyn¹,Chapman Kevin T.,Weber Ann,Sebhat Iyassu K.,Makara Gergely M.

Affiliation:

1. Metabasis Therapeutics, Inc., 11119 North Torrey Pines Road, La Jolla California 92037, United States

Funder

Merck

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.7b01344

Reference52 articles.

1. Modulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity with cAMP and with protein fractions of rat liver cytosol